Efficacy

Clinical field study in dogs

A dog study to measure NOCITA® (bupivacaine liposome injectable suspension) effectiveness was conducted in 182 client-owned dogs undergoing knee surgery. The study design was a randomized, prospective, blinded, placebo-controlled, multicenter study using 5.3 mg/kg NOCITA by infiltration injection during surgery closure. Post-operative pain assessment was evaluated at 0-24 hours, 24-48 hours and 48-72 hours.

The primary variable for effectiveness was evaluated over the first 24-hour time interval. The percent of treatment success for NOCITA was statistically significantly greater than placebo at the first 24-hour time interval (P = 0.0322). The 24-48 hour and 48-72 hour time intervals were evaluated as secondary variables and support effective use of NOCITA for up to 72 hours of analgesia. They were statistically significantly greater than placebo, with P-values of 0.0402 and 0.0432, respectively.

For dogs that were deemed treatment failures over any time interval, the failure was carried forward to all subsequent time intervals. Therefore, the time intervals for evaluating treatment success are equivalent to 0-24 hours, 0-48 hours, and 0-72 hours.

clinical field study chart

Now Approved For Cats

NOCITA is now FDA-approved for use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy. Please see the full Prescribing Information for more detail.

Clinical field study in cats

Effectiveness in cats was demonstrated in a multi-center, placebo-controlled, randomized and masked field study in client-owned cats undergoing owner-elective bilateral forelimb onychectomy. In this study, 241 cats were enrolled in the study and randomized to treatment with NOCITA® (bupivacaine liposome injectable suspension) or saline placebo.

Pain was assessed by trained observers using a modified version of the UNESP-Botucatu Multidimensional Composite Pain Scale for up to 72 hours. The primary variable for effectiveness was evaluated over the first 24-hour time interval. The percent of treatment success for NOCITA was significantly greater than saline for the 0-24 hour time interval (75.2 percent; p =0.0252). The 0-48 hour and 0-72 hour time intervals were evaluated as secondary variables and support effective use of NOCITA for up to 72 hours of analgesia.

Clinical References

Your convenient one-stop source for viewing, downloading and sharing important information.

Learn more >

Continuing Education

Complete an educational online course designed for Veterinarians and Veterinary Technicians to stay ahead of current trends and up-to-date on cutting-edge techniques.

Begin course now >

News

Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Visit >

Experience the Difference

“We began using Nocita on canine patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results.  The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively.  Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications.  Nocita has quickly become standard protocol for analgesia on our canine cruciate ligament stabilization procedures.” 

Veterinary Surgeon

Milwaukee WI

DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

CAT INDICATION: For use as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

ENTYCE logo

Finally, appetite stimulation is in your control.

ENTYCE® (capromorelin oral solution) is the ONLY FDA-approved veterinary therapeutic designed to safely and effectively stimulate appetite in dogs. Administered orally once a day, ENTYCE is appropriate for treating inappetence caused by chronic and acute conditions.

VIEW WEBSITE

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.